Catalyst Wire Dossier Catalyst Wire Dossier

Exelon Patch (rivastigmine transdermal patch)

rivastigmine transdermal patch · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Exelon Patch (rivastigmine transdermal patch), covering 2013-02-11 to 2013-02-11. Get the full timeline:

Most recent: Clinical Trial Update: Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 [Phase 4]

See pricing